MatthewDHellmannMD

PubMed

• 1 citations
  Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
  Elkrief, A., Waters, N., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N., Lumish, M., Giardina, P., Chaft, J., Eng, J., Motzer, R.,...> ;Cancer Immunology Research. 2024 Mar 4
• 1 citations
  Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
  Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Panagiotis Kourtesis, Maria L Asc...> ;Journal for Immunotherapy of Cancer. 2024 Feb 2
• 3 citations
  Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
  Danish Memon, Adam J Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi...> ;Cancer Cell. 2024 Feb 12
• Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.
  Wang, Y., Peng, G., Gu, J., Gainor, J., Mino-Kenudson, M., Riess, J., Velcheti, V., Hellmann, M., Zhao, H., Schalper, K., Lopez de Rodas, M.> ;Clinical Cancer Research. 2024 Mar 1
• 2 citations
  Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
  Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Jacklynn V Egger, Hira Rizvi, Rohit Thummalapalli, Guiseppe Lamberti, Andrew Plodkowski, Ma...> ;The Oncologist. 2023 Nov 2
• 3 citations
  Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
  Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V Alessi, Federica Pecci, Giuseppe Lamberti, Ale...> ;Clinical Cancer Research. 2023 Nov 1
• 2 citations
  Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
  Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, Matthew A Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne W Y Chiu, Jong-Seok Lee, James Chih-...> ;Nature Medicine. 2023 Jul 1
• 1 citations
  Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors.
  Gabriel Espinosa-Carrasco, Aurora Scrivo, Paul Zumbo, Asim Dave, Doron Betel, Matthew Hellmann, Bryan M Burt, Hyun-Sung Lee, Andrea Schietinger> ;Biorxiv. 2023 Jul 3
• 1 citations
  Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
  Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe L...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• 1 citations
  The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.
  Noura J Choudhury, Jessica A Lavery, Samantha Brown, Ino de Bruijn, Justin Jee, Thinh Ngoc Tran, Hira Rizvi, Kathryn C Arbour, Karissa Whiting, Ronglai Shen, Matthew H...> ;Clinical Cancer Research. 2023 Sep 1
• 11 citations
  Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
  Charles M Rudin, David Balli, W Victoria Lai, Allison L Richards, Evelyn Nguyen, Jacklynn V Egger, Noura J Choudhury, Triparna Sen, Andrew Chow, John T Poirier, Willia...> ;Journal of Thoracic Oncology. 2023 Sep 1
• 13 citations
  Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
  Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Gr...> ;Nature Genetics. 2023 May 1
• 5 citations
  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
  Naiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Sarah B Goldberg, Matthew D Hellmann, Ranee Mehra, Jong Chul Park, Harriet Kluger, Hu...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 4 citations
  Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
  Laurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, Matthew D Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H Schwartz, Binsheng Zha...> ;Journal of Thoracic Oncology. 2023 May 1
• 18 citations
  The ectonucleotidase CD39 identifies tumor-reactive CD8T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
  Chow, A., Uddin, F., Liu, M., Dobrin, A., Nabet, B., Mangarin, L., Lavin, Y., Rizvi, H., Tischfield, S., Quintanal-Villalonga, A., Chan, J., Shah, N., Allaj, V., Manoj...> ;Immunity. 2023 Jan 10
• 7 citations
  Widespread hypertranscription in aggressive human cancers.
  Matthew Zatzman, Fabio Fuligni, Ryan Ripsman, Tannu Suwal, Federico Comitani, Lisa-Monique Edward, Rob Denroche, Gun Ho Jang, Faiyaz Notta, Steven Gallinger, Saravana ...> ;Science Advances. 2022 Nov 25
• 8 citations
  Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
  H Borghaei, T-E Ciuleanu, J-S Lee, A Pluzanski, R Bernabe Caro, M Gutierrez, Y Ohe, M Nishio, J Goldman, N Ready, D R Spigel, S S Ramalingam, L G Paz-Ares, J F Gainor,...> ;Annals of Oncology. 2023 Feb 1
• 39 citations
  Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
  Justin Jee, Emily S Lebow, Randy Yeh, Jeeban P Das, Azadeh Namakydoust, Paul K Paik, Jamie E Chaft, Gowtham Jayakumaran, A Rose Brannon, Ryma Benayed, Ahmet Zehir, Mar...> ;Nature Medicine. 2022 Nov 1
• 13 citations
  Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort.
  Kanika Arora, Thinh N Tran, Yelena Kemel, Miika Mehine, Ying L Liu, Subhiksha Nandakumar, Shaleigh A Smith, A Rose Brannon, Irina Ostrovnaya, Konrad H Stopsack, Pedram...> ;Cancer Discovery. 2022 Nov 2
• 63 citations
  Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.
  Rami S Vanguri, Jia Luo, Andrew T Aukerman, Jacklynn V Egger, Christopher J Fong, Natally Horvat, Andrew Pagano, Jose de Arimateia Batista Araujo-Filho, Luke Geneslaw,...> ;Nature Cancer. 2022 Oct 1
• 101 citations
  Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-...
  Vaz, V., Biagio Ricciuti, Xinan Wang, Joao V Alessi, Hira Rizvi, Navin R Mahadevan, Yvonne Y Li, Andrew Polio, James Lindsay, Renato Umeton, Rileen Sinha, Natalie I Vo...> ;JAMA Oncology. 2022 Aug 1
• 9 citations
  Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.
  Semanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, Yelena Kemel, Esther Drill, Hira Rizvi, Kaitlyn Tkachuk, Aliya Khurram, Michael F Walsh, Marjorie G Zauder...> ;Cancer Epidemiology, Biomarkers & Prevention. 2022 Jul 1
• 10 citations
  Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer.
  Adam J Schoenfeld, Hira A Rizvi, Danish Memon, Narek Shaverdian, Matthew J Bott, Jennifer L Sauter, C Jillian Tsai, Jayon Lihm, David Hoyos, Andrew J Plodkowski, Rocio...> ;Clinical Cancer Research. 2022 Sep 1
• 8 citations
  Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.
  Sara E Schad, Andrew Chow, Levi Mangarin, Heng Pan, Jiajia Zhang, Nicholas Ceglia, Justina X Caushi, Nicole Malandro, Roberta Zappasodi, Mathieu Gigoux, Daniel Hirschh...> ;The Journal of Experimental Medicine. 2022 Jun 6
• 45 citations
  Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.
  Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, Ila J Datar, Mari Mino-Kenudson, German Corredor, Cristian Barrera, Lindsey Behlman, David L Rimm, Roy S Herbst, ...> ;Journal for Immunotherapy of Cancer. 2022 Jun 1
• Join now to see all

Lectures

• A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors. 
  2019 ASCO Annual Meeting - 6/1/2019
• Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease. 
  2019 ASCO Annual Meeting - 6/1/2019